Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells. (5th November 2018)

• Record Type: Journal Article
• Authors: Tang, Xiaolong; Xie, Chunmei; Jiang, Zhenyou; Li, Amin; Cai, Shiyu; Hou, Changhao; Wang, Jian; Liang, Yong; Ma, Dong
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 46(2018)Supplement 2
• Page Start: 1063
• Page End: 1073
• Publication Date: 2018-11-05
• Subjects: Non-Hodgkin's lymphoma -- mTOR -- signal pathways -- rituximab -- nanoparticles -- TOR serine-threonine kinases -- AZD-2014; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2018.1478844
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: The mTOR signal pathway is often highly activated in B-cell non-Hodgkin's lymphoma (NHL) and promotes cancer progression and chemo-resistance. Therefore, the pathways of mTOR are an important target for drug development in this disease. In the current study, we developed a rituximab (anti-CD20)-modified mTOR inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) for trial of its anti-NHL effect. In a cultured NHL cell line, Ab-NPs-AZD-2014 inhibited cancer cell growth, induced cell apoptosis, and blocked activation of mTORC1 and mTORC2 in Raji cells. These results indicate that antibody modification and nanomaterial loading of AZD-2014 with anti-CD20 significantly improved efficacy of AZD-2014 against NHL cells. This approach may ultimately deserve testing in therapy against NHL.